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Gastrin isoforms, acting through a variety of receptors, have proliferative and anti-apoptotic effects on gastrointestinal (GI) cancers. A
small interfering RNA (siRNA) targeting the gastrin gene was used to investigate the role of endogenous gastrin in GI cancer cell
survival. Downregulation of the gastrin gene in siRNA-transfected cells was measured using real-time reverse transcriptase–PCR. The
most effective siRNA was tested in a panel of GI cancer cell lines at various concentrations and time points, and the effect on cell
survival and apoptosis was measured using methyl thiazoyl tetrazolium (MTT) and caspase 3 activation assays. Gastrin siRNA reduced
gene expression by more than 90% in a range of GI cancer cell lines. Downregulation of the gastrin gene was dose-dependent and
effective over approximately 1 week in vitro. However, downregulation at the protein level was delayed by 3–4 days. Gastrin siRNA-
transfected cells showed up to a 60% reduction in growth and up to a 50% increase in apoptosis compared with control siRNA-
transfected cells. The effects were most marked in the cell line with the highest constitutive level of gastrin gene expression (human
metastatic colon, C170HM2) and in epidermal growth factor (EGF)-treated cells as the gastrin promoter contains an EGF-response
element, gERE. The ability of the siRNAs to reduce survival of these GI cell lines is further evidence of the importance of autocrine
and/or intracrine gastrin loops in GI cancer, where expression of the gastrin gene and autonomous gastrin appears widespread.
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Gastrin is produced by G cells in the antral mucosa, and in
addition to its established role in gastric acid secretion, it plays a
major role in tumorigenesis in the gastrointestinal (GI) tract.
Gastrin expression is frequently increased in colonic, pancreatic
and gastric adenocarcinomas compared with normal mucosa
(Finley et al, 1993; Goetze et al, 2000; Henwood et al, 2001). It is
expressed early in the development of GI adenocarcinomas (Smith
and Watson, 2000; Henwood et al, 2001), and in an APC
Min mouse
model, hypergastrinaemia promoted the progression of premalig-
nant lesions (Watson and Smith, 2001). Tumour growth factor-
alpha and epidermal growth factor (EGF) are involved in
upregulation of gastrin expression in a number of colon cancer
cell lines through binding to an established EGF response element,
gERE, within the gastrin promoter (Howell et al, 1995; Watson
et al, 2000).
In G cells, gastrin is processed to a 17-amino-acid amidated
active product. However, in GI epithelial cells, processing is
incomplete, resulting in secretion of the precursor peptide,
progastrin, and a range of intermediate products, of which the
most well-characterised is gly-gastrin (Rehfeld et al, 2004).
Whereas amidated gastrin acts through the CCK-2 receptor
(CCK-2R) (Shulkes and Baldwin, 1997), progastrin and gly-gastrin
bind with low affinity to this receptor (Baldwin et al, 2001;
Dockray et al, 2001). Furthermore, the biological effects of
progastrin and gly-gastrin are not blocked by CCK-B receptor
antagonists (Seva et al, 1994; Stepan et al, 1999; Baldwin et al,
2001), and amidated gastrin and gly-gastrin stimulate different
downstream signalling events (Todisco et al, 2001). Potential
alternative receptors for progastrin and gly-gastrin have been
suggested (Seva et al, 1994; Baldwin, 1995a; Singh et al, 1995; Smith
et al, 2002; Ahmed et al, 2004).
Exogenously applied gastrin and its precursors have a range of
downstream effects on GI cancer cells. Amidated gastrin, gly-
gastrin and progastrin promote growth of a range of cell lines
in vitro and in vivo (Watson et al, 1989; Seva et al, 1994; Baldwin,
1995b; Stepan et al, 1999; Baldwin et al, 2001) and upregulate
expression of a range of anti-apoptotic proteins, including Akt and
bcl-2 (Konturek et al, 2003; Harris et al, 2004a; Ramamoorthy et al,
2004). Gly-gastrin promotes invasion of human colon cancer cells
by upregulating expression of matrix metalloproteinases (Baba
et al, 2004), by increasing the rate of metastasis formation in vivo
(Kermorgant and Lehy, 2001) and by promoting blood vessel
formation through the stimulation of endothelial cells (Clarke et al,
2006).
The role of endogenously produced gastrin has been investi-
gated through the use of antibodies to gastrin and CCK-2R
antagonists (Hoosein et al, 1988; Smith et al, 1996). However, such
reagents may underestimate the role of gastrin, as a cocktail of
reagents would be needed to inhibit all biologically active products
of the gastrin gene and may be ineffective against gastrin-derived
peptides that have not yet been identified.
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gastrin expression in a range of GI cancer cells in order to
investigate the role of endogenously produced gastrin. Gastrin
antisense-transfected cell lines have previously been shown to have
reduced growth in vitro and are poorly tumorigenic in vivo (Singh
et al, 1996; Harris et al, 2004b; Smith et al, 2004). However, siRNAs
potentially provide a more powerful and specific mechanism for
the downregulation of genes than traditional antisense approaches
(Aoki et al, 2003) and have stringent sequence specificity (Elbashir
et al, 2001a). The data described in this paper demonstrate a
protective role for endogenous gastrin in a range of GI cancer cells
using an siRNA specific for gastrin.
MATERIALS AND METHODS
Cell culture
PAN-1 is a human pancreatic cell line derived from a poorly
differentiated human pancreatic adenocarcinoma within the
Academic Unit of Cancer Studies, University of Nottingham, UK.
HCT116, a poorly differentiated human colon cell line, was
obtained from ECACC (ref. no. 91091005). C170HM2 is a human
colorectal tumour cell line originally derived from a poorly
differentiated tumour (Watson et al, 1993). MGLVA1 is an ascitic
variant of the gastric cell line, MKN 45G (Watson et al, 1990).
All cell lines were routinely cultured in RPMI 1640 culture
medium (Gibco, Paisley, UK) containing 10% (v/v) heat-inacti-
vated fetal bovine serum (Sigma, Poole, UK) at 371Ci n5 %C O 2
and humidified conditions.
Small interfering RNA synthesis
Target sites within the gastrin gene for siRNA synthesis were
chosen for the following properties (Elbashir et al, 2001b):
(a) preceded by AA in the gene sequence
(b) avoidance of the extreme 50 or 30 ends of the gene
(c) 30–60% GC content
(d) absence of long stretches of A’s
(e) lack of homology with other genes using BLAST
Their sequences are given in Table 1. Initial experiments were
carried out with siRNAs synthesised in vitro using the Silencer
siRNA Construction Kit (Ambion, Austin, TX, USA), according to
the manufacturer’s instructions. Briefly, template DNA oligo-
nucleotides containing the sense or antisense of the target
sequence, followed by the leader sequence CCTGTCTC at the 30
end, were synthesised commercially (Helena Bioscience, Gates-
head, UK). The T7 promoter-containing primer was annealed to
the template oligonucleotides and dsDNA created using Klenow
DNA polymerase. The sense and antisense dsDNAs were used as
templates to synthesise the antisense or sense strands of RNA,
respectively, using T7 RNA polymerase. The two RNA strands were
annealed together, digested with DNase and RNase to remove the
template DNA and leader sequence, then column-purified and
stored at  801C. The concentration of the siRNAs was calculated
by measuring their optical density (OD) at 260nm.
Small interfering RNAs were also synthesised commercially
as separate strands that were annealed and PAGE-purified
(Dharmacon, Lafayette, CO, USA). A fluorescent version of tg8
was also synthesised with a TAMRA label at the 50 end of the sense
strand.
Small interfering RNA transfection
Cells (5 10
4) were plated out in 24-well plates and cultured
overnight in normal growth medium. In initial experiments, two
transfection reagents, siPortAmine and siPortLipid (Ambion),
were tested under a range of conditions to optimise the protocol.
The following protocol was used to generate the data described in
the paper. Each well was transfected using 4ml of siPortAmine and
1ml of siRNA, to give final concentrations of 25nM of in vitro-
synthesised siRNAs or up to 0.5mgml
 1 of commercially
synthesised siRNA. The siPortAmine was vortexed, added drop
by drop to 45ml Opti-MEM1 (Invitrogen, Paisley, UK), vortexed
and incubated for 30min at room temperature. The diluted
transfection reagent was added to the siRNA, mixed by pipetting
and incubated for a further 30min. The growth medium was
removed from the cells and replaced by 200ml Opti-MEM1 and
then overlaid with the transfection reagent:siRNA complex, with
rocking. The plates were incubated for 6h at 371C, 5% CO2, after
which 1ml growth medium was added and the plates were
returned to the incubator.
Real-time PCR
RNA was extracted using RNABee (Biogenesis, Poole, UK) and
complementary DNA (cDNA) synthesised using Superscript II and
random hexamers as described previously (McWilliams et al,
1998). For each RNA, a cDNA-negative control (no RT or primer)
was also synthesised. PCR for gastrin and the housekeeping gene
was routinely carried out using 5ml of 1:5 cDNA and 20mlo f
reaction mix consisting of 1  reaction buffer, 1:2000 SybrGreen,
MgCl2, dNTP mix, 1ml of primer and Hot GoldStar Taq
(Eurogentec, Romsey, UK). The sequences of the primers used
are shown in Table 2. In addition, oligoadenylate synthase 1 (OAS),
signal transducer and activator of transcription 1 (STAT1) and
hypoxanthine guanine phosphoribosyl transferase (HPRT) genes
were detected with Taqman primer sets (Applied Biosystems,
Warrington, UK), using the same reaction mix as above but
without SybrGreen.
Complementary DNAs were tested in triplicate and, in addition,
cDNA-negative and ‘no template’ controls were analysed to ensure
that the signal generated was derived from RNA and not from
genomic DNA, primer-dimers or any of the cDNA or PCR
reagents. The samples were run on a GeneAmp 5700 Sequence
Detector Real-Time PCR machine (Applied Biosystems) using the
following programme: 501C for 2min, 951C for 10min, 40 cycles of
951C for 15s and 601C for 1min with products being detected
Table 1 Gastrin siRNA target sequences
Target Target sequence % GC
Position
in gene
tg1 AAGCTTCTTGGAAGCCCCGCT 57.1 59
tg5 AAGAAGCAGGGACCATGGCTG 57.1 220
tg7 AAGAAGAAGAAGCCTATGGAT 38.1 245
tg8 AAGAAGAAGCCTATGGATGGA 42.9 248
tg9 AAGAAGCCTATGGATGGATGG 47.6 251
tg10 AAGCCTATGGATGGATGGACT 47.6 254
scr tg5 AAGAGATGTAAGGCCAGGCCG 57.1 NA
scr tg8 AAGCGAAGAAACGAGGTGTAT 42.9 NA
NA: not applicable.
Table 2 Primers used for real-time PCR
Primer Primer sequence (50- 30)
Gastrin F CCACACCTCGTGGCAGAC
Gastrin R TCCATCCATCCATAGGCTTC
HPRT F GACCAGTCAACAGGGGACAT
HPRT R CGACCTTGACCATCTTTGGA
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susing SYBR Green or the fluorescent Taqman probe. The number
of cycles required to reach a fluorescence threshold (Ct) during the
exponential phase of amplification was determined for the test
gene and for the housekeeping gene HPRT. Results are usually
presented as relative gene expression in comparison to HPRT and
a reference treatment using the 2
 DDCt method (Livak and
Schmittgen, 2001), where
Relative gene expression ¼
2 ½Ctðtest geneÞ CtðHPRTÞ test condition
2
 ½Ctðtest geneÞ CtðHPRTÞ reference condition
To demonstrate differences in expression levels between different
cell lines, data are shown using the 2
 DCt equation where
2 DCt ¼ 2 ½Ctðtest geneÞ CtðHPRTÞ test condition
95% confidence intervals for the mean gastrin expression were
calculated based on the variation between the replicates for each
sample and are indicated on each graph as error bars.
Green fluorescent protein-tagged gastrin
The complete gastrin coding sequence was amplified by PCR and
cloned upstream of the green fluorescent protein (GFP) coding
sequence in the plasmid pHRGFP-C (Stratagene, LaJolla, CA,
USA), under the control of a CMV promoter, using the BamH1 and
XhoI restriction sites to create a plasmid pGasGFP. A complete
Kozak sequence was incorporated into the forward primer,
involving modification of the fourth nucleotide of the gastrin
coding sequence from C to G (indicated in the primer sequence by
underlining). The primers used were as follows:
Forward: CGCGGATCCGCCGCCGCCATGGAGCGACTGTG TGTG
Reverse: CCGCCGCTCGAGGCCGAAGTCCATCCATC
The unmodified pHRGFP-C plasmid was used as a vector
control. As it lacks a Kozak sequence, no GFP expression was
expected.
Dual transfection of plasmids and siRNAs was carried out by
preparing the siRNA transfection mix as above but in half the
volume, and preincubating 500ng of plasmid with 1ml Lipofecta-
mine (Invitrogen, Paisley, UK) in 25ml serum-free medium. The
two transfection reagents were then mixed immediately before
addition to the cells.
Antibody staining of cytospins
Following transfection, cells were stored, fixed in 4% formalin
overnight at 41C, then washed twice in PBS after each of the
following steps. Cytospins were made in a Shandon cytospin 4
using 10
4 cells per slide. Cells were permeabilised by incubation
with PBS containing 0.5% Triton X-100 for 5min at 41C.
Nonspecific binding sites were blocked by a 30min incubation at
room temperature in PBS containing 3% BSA and 1% glycine
followed by PBS containing 10% normal swine serum (NSS). The
primary antibody (rabbit anti-progastrin antibody, raised against
amino acids 6–14 of progastrin conjugated to diphtheria toxin
(DT) and purified against the BSA peptide conjugate; (Aphton
Corp., Philadelphia, PA, USA) or control antibody (rabbit anti-DT)
was added at a final concentration of 2.5mgml
 1 in PBS containing
1% NSS and incubated overnight at 41C. Binding of the antibody
was detected using FITC-conjugated swine anti-rabbit immuno-
globulin at a dilution of 1:40 (Dako, Ely, UK) and the cells were
counterstained with Hoechst dye before examination under a
fluorescent microscope.
Growth assays
Cell growth was measured using a standard methyl thiazoyl
tetrazolium (MTT) assay (Watson et al, 1996). Briefly, following
transfection with siRNAs, cells were grown overnight, then
trypsinised, plated out into 96-well plates as replicates and
incubated overnight in growth medium. The following day, the
medium was replaced by RPMI 1640 culture medium supplemen-
ted with 1% serum or serum-free OptiMem1, and the cells were
grown for a further 96h. In some experiments, OptiMem1 was
supplemented with 10nM amidated gastrin (G17, Aphton, USA),
10nM glycine-extended gastrin (Gly-G17, Aphton, USA) or the
CCK2-R inhibitor, YM022 (James Black Foundation, Dulwich, UK)
at 500nM. At intervals following transfection, the medium was
replaced by fresh medium containing MTT at 1mgml
 1 and
incubated for 4h. The medium was removed, the incorporated
MTT dissolved in DMSO and the OD at 550nm was read.
Caspase 3 inhibitor assay
Cells undergoing apoptosis were identified by addition of a
fluorescent caspase 3 inhibitor, FITC-DEVD-FMK (Calbiochem,
Nottingham, UK), according to the manufacturer’s instructions. Cells
were harvested using trypsin–EDTA, resuspended in fresh medium
and incubated with the inhibitor at the recommended final working
concentration for 1h at 371C. The cells were washed twice in the wash
buffer provided, fixed in formalin and analysed on a Beckman-
Coulter XL-MCL flow cytometer. The percentage of apoptotic cells
was calculated, using untreated cells to define the baseline.
Statistical analysis
The significance of differences in gene expressing between cell
lines was calculated using ANOVA with the Bonferroni multiple
comparison test. The significance of differences between growth
and rates of apoptosis in cells transfected with the gastrin siRNA
and control siRNA was measured using the Student’s t-test.
Differences were considered to be significant if Po0.05.
RESULTS
Localisation of suitable targets within gastrin
A fluorescent TAMRA-labelled siRNA (tg8) was used to measure
the efficiency of transfection. At 24h after transfection, almost
100% of the cells were fluorescent with the signal associated with
vesicle-like structures in the cytoplasm of the cells (Figure 1A).
Small interfering RNAs directed against six different targets within
gastrin and a control siRNA consisting of a scrambled version of
the tg5 sequence were then used to transfect PAN-1 cells. Gene
expression was measured 24h after transfection by real-time PCR.
Use of the most effective siRNAs, tg8 and tg9, resulted in a 93%
decrease in gastrin gene expression relative to that in cells treated
with the control siRNA and the housekeeping gene HPRT. The
remaining siRNAs gave between 64 and 86% downregulation of the
gastrin gene (Figure 1B). Tg8 was used for the remainder of the
studies and synthesised commercially together with a scrambled
control.
The gastrin siRNA is effective in a range of cell lines with
different gastrin expression levels and is able to overcome
transcriptional upregulation of the gastrin gene by EGF
The tg8 and scrtg8 siRNAs were used to transfect three additional
cell lines, HCT116 (colorectal), C170HM2 (liver-metastasising
variant of a colorectal cell line) and MGLVA1 (gastric). Basal
gastrin gene expression in the four cell lines is shown in Figure 2A.
Expression in HCT116 and C170HM2 cells was significantly higher
(approximately 15  and 20 , respectively; Po0.001 for both)
than that in the PAN-1 and MGLVA1 cells. Nonetheless, in each of
the cell lines, between 80 and 95% downregulation of the gastrin
gene was achieved in cells treated with gastrin siRNA (Figure 2B).
In addition, the ability of the gastrin siRNA to overcome
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supregulation of the gastrin gene by EGF was demonstrated in PAN-
1 cells (Figure 2C).
Downregulation of the gastrin gene by the siRNA is dose-
dependent and is maintained in vitro for more than 1 week
The tg8 and scrtg8 siRNAs were tested at a range of concentrations
against HCT116 cells, one of the cell lines expressing the highest
level of gastrin RNA. Downregulation of the gastrin gene was dose-
dependent (Figure 3), with 60% downregulation of the gene still
achieved at the lowest effective dose of siRNA (0.02mg).
To investigate the duration of the effectiveness of the siRNA,
PAN-1 cells were transfected with 0.5 or 0.05mg tg8 or scrtg8
siRNA, harvested at a range of time intervals following transfection
and analysed for gene expression by real-time PCR. The effect of
the tg8 siRNA was prolonged. At the highest concentration of
siRNA used, 90% downregulation of the gene was maintained up to
7 days after transfection, dropping to 80% at day (d) 11. At the
lower concentration of siRNA, 85% downregulation was main-
tained up to d7, but dropped to 53% by d11 (Figure 4). When a
similar experiment (data not shown) was carried out with HCT116
cells, which have a higher basal level of gastrin expression, 60%
downregulation of the gene was maintained up to d8 after
transfection, provided that the higher concentration of siRNA
was used. Thus, for the remainder of experiments, cells were
transfected with 0.5mg siRNA per 5 10
4 cells.
The innate interferon response is not induced by the
gastrin siRNA
To investigate whether transfection with gastrin siRNA results in
induction of the innate interferon response, expression of STAT1
and OAS was measured in HCT116 cells transfected with tg8 or
Gastrin siRNA sequence
tg1 tg5 tg7 tg8 tg9 tg10 scr tg5
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Figure 1 (A) siRNA transfection efficiency. PAN-1 cells transfected with
a TAMRA-labelled gastrin siRNA 24h post-transfection ( 64 magnifica-
tion). The siRNA is associated with vesicle-like structures in the cytoplasm
of the cells. (B) Expression of the gastrin gene in cells transfected with
different gastrin siRNAs. PAN-1 cells were transfected with six different
gastrin siRNAs and gastrin expression was measured by real-time PCR.
Expression relative to cells transfected with the scrambled control siRNA
(scrtg5) and the housekeeping gene, HPRT, is shown. Error bars indicate
the 95% confidence intervals. The relative position of each siRNA within
the gastrin sequence is indicated.
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Figure 2 Effectiveness of gastrin siRNA in a range of GI cancer cell lines.
(A) Relative expression of gastrin in four cell lines (PAN-1, HCT116,
MGLVA1 and C170HM2) is shown using the 2
 DCt formula. A significant
difference in expression compared with that in PAN-1 (Po0.001) is
indicated by *. (B) The downregulation of gastrin gene expression in cells
treated with the tg8 gastrin siRNA is shown relative to cells treated with
the control scrtg8 siRNA using the 2
 DDCt formula. (C) Gene expression in
PAN-1 cells on d2 after transfection with gastrin (tg8) or control (scrtg8)
siRNA and 24h treatment with or without 10mgml
 1 EGF. Data are
expressed relative to the housekeeping gene, HPRT. Significant differences
(Po0.001) are indicated by *. Error bars indicate the 95% confidence
intervals.
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sscrtg8 siRNA or mock-transfected cells treated with the transfec-
tion reagent but without siRNA. Whereas there was a significant
difference comparing gastrin expression (Figure 4A) in tg8-treated
cells with scrtg8- or mock-treated cells (P¼0.005), there was no
significant difference in STAT1 (Figure 4B) or OAS (Figure 4C)
expression (P40.28), suggesting that the innate interferon
response is not induced by these siRNAs under these conditions.
Downregulation of GFP-tagged and endogenous gastrin
Owing to the complexity of the products arising from the gastrin
gene and the low levels of gastrin protein produced by GI tumour
cells, the effect of siRNA transfection on gastrin protein expression
was initially analysed using HCT116 cells transfected with a GFP-
tagged gastrin gene. Four replicates of each cotransfection were
carried out. One replicate for each treatment is shown in Figure 5A
and B. The average percentage of fluorescent cells following
transfection with pGasGFP and the control siRNA was 19.8,
whereas only 4.8% of cells cotransfected with pGasGFP and the
gastrin siRNA were positive. Thus, there was a significant
reduction in the proportion of GFP-tagged gastrin-expressing cells
within 24h of treatment with the gastrin siRNA (Po0.00001).
However, a different pattern was seen when endogenous gastrin
expression in siRNA-treated HCT116 cells was measured using a
monoclonal antibody to amino acids 6–14 of progastrin. There
was no apparent difference between tg8-and scrtg8-treated cells at
early time points with the first detectable reduction in progastrin
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Figure 3 Concentration-dependent effects of the gastrin siRNA and
longevity of downregulation of the gastrin gene. (A) Gastrin gene
expression in HCT116 cells transfected with a range of concentrations of
gastrin (tg8) siRNA, expressed relative to the housekeeping gene, HPRT,
and cells transfected with the same concentration of the control (scrtg8)
siRNA. Error bars indicate the 95% confidence intervals. (B) Gene
expression in PAN-1 cells at d1, d4, d7 or d11 after transfection with 0.5 or
0.05mg gastrin (tg8) or control (scrtg8) siRNA. Data are expressed relative
to the control siRNA and the housekeeping gene, HPRT. Error bars
indicate the 95% confidence intervals.
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Figure 4 Absence of induction of the innate interferon response by
gastrin siRNA. Gastrin, OAS and STAT1 gene expression in PAN-1 cells
treated with gastrin (tg8), control (scrtg8) siRNA or no siRNA (mock
transfected). Error bars indicate the 95% confidence intervals.
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there was still some residual staining of tg8-treated cells.
Endogenous gastrin enhances survival of serum-starved GI
cancer cells
To measure the role of endogenous gastrin in cell survival
following serum starvation, PAN-1 were cultured in medium
supplemented with serum or serum-free medium (Figure 6A). Cell
survival was assessed at a range of time points using an MTT assay.
Under both sets of conditions, growth was lower in the gastrin
siRNA-treated cells than in cells treated with the control siRNA.
However, the effects reached significance only under serum-free
conditions (Po0.001), with 32% inhibition in serum-free medium
compared with 13% (NS) in medium supplemented with serum at
d8. Consistent with the delay in downregulation of endogenous
gastrin protein expression following siRNA treatment, clear
differences in cell survival were not apparent until approximately
d6 following transfection.
As the gastrin siRNA reduces induction of the gastrin gene
expression by EGF, cell survival was measured for each cell line in
the presence or absence of 10mgml
 1 EGF on d6 after transfection.
The experiment was carried out on a minimum of three separate
occasions and representative data for a single experiment for each
cell line are shown in Figure 7. Although there was some variation
between experiments, in all four cell lines there was reduced cell
survival in the tg8-compared with the scrtg8-treated cells. Reduced
thymidine incorporation was also observed in PAN-1 cells over a
similar time frame (data not shown).
The effects were most marked in the C170HM2 cells, which
expressed the highest level of gastrin. In the absence of EGF, there
was a significant reduction in cell survival on each of the three
occasions they were tested (% cell survival of 63.1, 75.0 and 68.5),
whereas in the remaining three cell lines, in the absence of EGF,
significance was reached in only a proportion of separate
experiments. Similar reductions in growth were seen in PAN-1
and C170HM2 cells treated with two other gastrin siRNAs, tg5 and
tg7 (data not shown), suggesting that this effect is specifically related
to downregulation of the gastrin gene. In cells treated with EGF, a
significant difference in growth was seen in every independent
experiment and the percentage reduction in growth was greater.
Downregulation of endogenous gastrin leads to increased
apoptosis in GI cancer cells exposed to serum-free
conditions
As gastrin is thought to be anti-apoptotic as well as acting as a
growth factor, the effect of downregulation of endogenous gastrin on
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Figure 5 Downregulation of GFP-tagged and endogenous gastrin protein expression by gastrin siRNA. Cells transfected with (A) a GFP-tagged gastrin
plasmid and treated with control scrtg8 siRNA or (B) gastrin tg8 siRNA are shown 24h after transfection. The percentage of positive cells is indicated and
there was a significant difference (Po0.0001) between the two treatments. Cells transfected with (C) scrtg8 or (D) gastrin tg8 siRNA were immunostained
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Figure 6 Survival of gastrin siRNA-transfected cells in the presence and
absence of serum. Growth of PAN-1 cells transfected with gastrin tg8
siRNA or the control scrtg8 siRNA in serum containing 10% or serum-free
medium over 8 days following transfection. At d3 and d6, there was
significantly lower survival in the tg8- treated cells than the scrtg8-treated
cells (P¼0.004 and 0.001 for serum and no serum, respectively, at d3, and
P¼0.06 and 0.02, respectively, at d6).
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sapoptosis in the four cell lines following exposure to serum-free
conditions was also investigated. A fluorescent caspase 3 inhibitor
was used to identify cells undergoing apoptosis, and the proportion
of apoptotic cells, following transfection with the gastrin or control
siRNA, was measured. Basal levels of apoptosis in the cell lines in
serum-free medium varied between the different cells and in
different experiments but was in the range of 10–30%. The data at
d4 following transfection are shown in Figure 8. There was increased
apoptosis in the cells treated with the gastrin siRNA compared with
the control siRNA, except in the MGLVA1 cells. In the absence of
EGF, the difference was significant in the PAN-1 and C170HM2 cells.
The effect was enhanced in the presence of EGF, with a significant
difference seen additionally in the HCT116 cells. Significance was not
reached in the MGLVA1 cells under either condition.
Amidated gastrin and glycine-extended gastrin enhance
growth of gastrin siRNA-treated cells
To investigate the ability of exogenous gastrin to restore growth of
cells treated with the gastrin siRNA, siRNA-transfected cells were
treated with either amidated (G17) or glycine-extended gastrin
(Gly-G17) at 10nM. The growth of control siRNA-treated
C170HM2s was increased by 23 and 56%, following treatment
with G17 and Gly-G17 respectively, and growth of the control
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Figure 8 Apoptosis in gastrin siRNA-transfected cancer cells. Proportion of apoptotic cells at d4 following treatment with gastrin (tg8) or the control
(scrtg8) siRNA in the presence or absence of 10mgml
 1 EGF. Apoptosis is shown relative to scrtg8-treated cells. Significant differences (Po0.05) are
indicated by *. (A) PAN-1, (B) C170HM2, (C) HCT116 and (D) MGLVA1.
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(Figure 9A). There was a significantly greater increase in growth in
gastrin siRNA-transfected cells treated with G17 and GlyG17 than
in control siRNA-treated cells (Po0.001 for both).
Treatment of gastrin siRNA-treated cells with YM022
further reduced the survival of gastrin siRNA-transfected
cells
The effect of the CCK2-R antagonist YM022 on survival of the
gastrin siRNA-transfected cells was investigated in PAN-1 and
C170HM2 cells. The antagonist had no significant effect on the
growth of the control siRNA-treated cells but significantly reduced
the survival of gastrin siRNA-transfected PAN-1 cells by 41%
(Figure 9B, P¼0.003). Survival of gastrin siRNA-transfected
C170HM2 cells was reduced by 23% following treatment with
YM022, but this did not reach significance.
DISCUSSION
Gastrin is involved in the establishment of a range of GI tumours.
Here, using an siRNA that specifically targets gastrin, we show that
endogenous gastrin plays a role in the survival of cell lines
representing gastric, colorectal and pancreatic adenocarcinoma.
Downregulation of gastrin resulted in reduced survival of cells
exposed to serum-free conditions and was attributable at least in
part to an increase in the rate of apoptosis in the gastrin siRNA-
treated cells.
Initially, a number of siRNAs directed against potential targets
within the gastrin gene were investigated for their effectiveness at
mediating downregulation of the gastrin mRNA transcript.
Interestingly, the most effective siRNAs were clustered towards
the 30 end of the transcript. This may be a result of easier access of
the siRNA to its target due to reduced structural complexity in this
region of the RNA as previously described (Luo and Chang, 2004;
Yoshinari et al, 2004). The effects of the gastrin siRNA appear to be
specific. The possibility of off-target effects (Scacheri et al, 2004)
and induction of the interferon response (Sledz et al, 2003) has
been suggested in the literature. A BLAST search was included in
the design of the siRNAs used in this study and no matches to
other genes were identified. Similar growth effects were seen with
two additional gastrin siRNAs, and in all experiments a scrambled
siRNA was used as a control for potential nonspecific effects due to
the addition of siRNAs to the cell or transfection. In addition, we
saw no induction of either OAS or STAT1 genes in response to the
gastrin or control siRNA and the delay in the effects of the siRNA
also argues against the involvement of the interferon response in
the growth effects observed as this innate response is generally
induced rapidly.
We were able to demonstrate rapid downregulation of plasmid-
encoded GFP-tagged gastrin peptides at the protein level within
24h of treatment with the gastrin siRNA. However, there was an
apparent delay of 2–3 days in downregulation of endogenous
gastrin protein. Similar effects have been described previously for
a number of genes (Wu et al, 2004) and may relate to slow rates of
turnover of individual proteins within the cell or mechanisms that
allow continued expression of protein from the small residual pool
of mRNA; such mechanisms may not be active on recombinant
vector-derived protein.
This apparent delay in downregulation of endogenous gastrin
protein correlated with the time frame for measurement of the
biological effects of downregulation of gastrin by the siRNA, which
were delayed to approximately d5 following transfection. Down-
regulation of gastrin in the presence of serum resulted in a
statistically significant reduction in cell survival, but the effect was
small. However, in serum-free conditions, downregulation of
gastrin reduced cell survival by up to 50% in the presence of
EGF, the effect being most marked in the colorectal cell lines,
especially C170HM2. This cell line has the highest constitutive
levels of gastrin expression and may, therefore, be more dependent
on gastrin for maintenance of the cell cycle.
The reduced survival of cells in which endogenous gastrin
has been knocked down is in part due to an increase in
apoptosis in these cells. The effects on apoptosis parallel the
results of the cell survival assays, with the strongest effects seen in
the colorectal cell lines, especially C170HM2, and with no
significant effects on apoptosis seen in MGLVA1. A raised level
of caspase 3 in cells treated with gastrin antisense and exposed to
camptothecin has been reported previously in HCT116 cells (Wu
et al, 2000).
Both gastrin and control siRNA-treated cells were responsive to
amidated and glycine-extended gastrin. Interestingly, the gastrin
siRNA-treated cells were more responsive, with not only greater
percentage increase but also a higher final cell number than the
control siRNA-treated cells treated with the peptides. This result
further suggests that downregulation of the gastrin gene may lead
to increased expression of the receptors for these peptides.
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Figure 9 Growth of siRNA-transfected cells in the presence of gastrin
peptides and a CCK2-R antagonist, (A) the growth of gastrin (tg8) or
control (scrtg8) siRNA-transfected C170HM2 cells treated with 10nM
amidated (G17) or glycine-extended (Gly-G17) gastrin. The percentage
increase in growth compared with transfected cells alone is indicated.
There was a significant increase in the growth of peptide-treated gastrin
siRNA-transfected cells compared with control siRNA-transfected cells
(Po0.001 for both G17 and GlyG17, indicated by *). (B) The growth of
gastrin (tg8) or control (scrtg8) siRNA-transfected Pan1 and C170HM2
cells treated with 500nM YM022 is shown. There was a significant further
reduction in cell survival in tg8-transfected Pan1 cells following treatment
with YM022 (41%, P¼0.003) is shown. There was a 23% reduction in cell
survival in C170HM2 cells but this did not reach significance.
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siRNA-transfected cells treated with the CCK2-R antagonist,
YM022. The control siRNA-treated cells were unresponsive to
YM022, suggesting that CCK2-R is not involved in the basal growth
of these cells. This is in keeping with our findings that classical
CCK2-R expression is undetectable in these cell lines by real-time
PCR (data not shown) or using a nested PCR method that avoids
potential artefacts associated with amplification of genomic DNA
(Grabowska et al, 2004). It suggests that the gastrin-dependent cell
survival, which is overcome by the gastrin siRNA, is not effected
through the classical CCK2-R.
However, there was a decrease in the survival of the gastrin
siRNA-treated cells in response to YM022. This could be explained
by upregulation of one or more gastrin receptors that are inhibited
by YM022, with either constitutive activity or with stimulation by
residual endogenous gastrin. Thus, the percentage reduction in cell
growth resulting from treatment with gastrin siRNA may be an
underestimate of the role of gastrin in the basal growth of these
cells if downregulation of gastrin leads to upregulation of
alternative pathways that enhance cell growth.
The ability of the gastrin siRNAs to reduce survival of these GI
cell lines is further evidence of the importance of autocrine and/or
intracrine gastrin loops in the growth of these GI cancer cells. The
effect of the gastrin siRNA is of a similar order of magnitude to
that which has been described before when antibodies to gastrin
peptides, receptor antagonists or antisense have been used to
downregulate gastrin (Hoosein et al, 1988; Singh et al, 1996; Smith
et al, 1996, 2004), and suggests that gastrin is only one of a number
of factors contributing to survival of GI cancer cells. However,
these data may also underestimate the role of endogenous gastrin.
In the case of antibodies or receptor antagonists, they are effective
against only a subset of gastrin isoforms. The siRNA described
here is able to effectively downregulate gastrin at the RNA level
and so should affect all products of the gastrin gene, but as
downregulation of the protein is delayed and incomplete, there is
only a narrow window in which the effect of gastrin knockdown
can be measured. Further investigation of the mechanisms
underlying gastrin translation and protein turnover would be
beneficial. In addition, future studies will require systems to
deliver the siRNA over a longer time frame, possibly through the
use of plasmid-encoded small hairpin siRNAs or development of
alternative approaches such as microRNAs that inhibit translation
of the gastrin transcript. This will provide a model that will allow a
more detailed study of the complex interactions between the
different isoforms of gastrin and gastrin receptors expressed by
these cells.
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